Laurent Greillier

9.1k total citations · 1 hit paper
206 papers, 3.0k citations indexed

About

Laurent Greillier is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, Laurent Greillier has authored 206 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 151 papers in Pulmonary and Respiratory Medicine, 119 papers in Oncology and 21 papers in Epidemiology. Recurrent topics in Laurent Greillier's work include Lung Cancer Treatments and Mutations (82 papers), Lung Cancer Research Studies (55 papers) and Occupational and environmental lung diseases (49 papers). Laurent Greillier is often cited by papers focused on Lung Cancer Treatments and Mutations (82 papers), Lung Cancer Research Studies (55 papers) and Occupational and environmental lung diseases (49 papers). Laurent Greillier collaborates with scholars based in France, United States and Italy. Laurent Greillier's co-authors include Fabrice Barlési, Pascale Tomasini, Céline Mascaux, Philippe Astoul, C. Doddoli, Benjamin Besse, M. Souquet-Bressand, Arnaud Scherpereel, Julien Mazières and Gérard Zalcman and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Laurent Greillier

188 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

2022 158 citations Arnaud Scherpereel, Laurent Greillier et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Laurent Greillier France	28	1.8k	1.6k	530	338	238	206	3.0k
Meghan J. Mooradian United States	19	1.2k 0.7×	1.8k 1.1×	472 0.9×	256 0.8×	282 1.2×	68	2.6k
Young Hak Kim Japan	30	1.7k 1.0×	1.9k 1.2×	644 1.2×	292 0.9×	279 1.2×	127	2.8k
Hidehito Horinouchi Japan	32	1.7k 0.9×	2.0k 1.2×	497 0.9×	271 0.8×	309 1.3×	225	3.0k
Sara Pilotto Italy	29	1.1k 0.6×	1.8k 1.1×	813 1.5×	324 1.0×	485 2.0×	187	2.9k
Panos Fidias United States	25	1.8k 1.0×	1.7k 1.0×	925 1.7×	170 0.5×	276 1.2×	58	3.0k
Adolfo Favaretto Italy	31	2.2k 1.2×	1.7k 1.1×	780 1.5×	371 1.1×	357 1.5×	136	3.7k
Bryan J. Schneider United States	26	1.2k 0.7×	1.6k 1.0×	613 1.2×	540 1.6×	334 1.4×	75	2.8k
Paolo Bidoli Italy	27	1.9k 1.1×	2.0k 1.2×	531 1.0×	190 0.6×	292 1.2×	127	3.1k
Tomonori Hirashima Japan	31	1.9k 1.1×	1.7k 1.0×	543 1.0×	148 0.4×	196 0.8×	146	2.7k
Paolo Maione Italy	31	2.0k 1.1×	2.2k 1.3×	1.1k 2.1×	233 0.7×	452 1.9×	138	3.6k

Countries citing papers authored by Laurent Greillier

Since Specialization

Citations

This map shows the geographic impact of Laurent Greillier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laurent Greillier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laurent Greillier more than expected).

Fields of papers citing papers by Laurent Greillier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laurent Greillier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laurent Greillier. The network helps show where Laurent Greillier may publish in the future.

Co-authorship network of co-authors of Laurent Greillier

This figure shows the co-authorship network connecting the top 25 collaborators of Laurent Greillier. A scholar is included among the top collaborators of Laurent Greillier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laurent Greillier. Laurent Greillier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Greillier, Laurent, Florian Guisier, Catherine Daniel, et al.. (2025). Real-world efficacy and safety of amivantamab in EGFR exon-20-mutant non-small cell lung cancer in a French early-access program: Amexon 20 GFPC study. Lung Cancer. 209. 108766–108766.

Remón, Jordi, Paolo Bironzo, Nicolas Girard, et al.. (2025). Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial. The Lancet Oncology. 26(9). 1215–1226. 1 indexed citations

Levallet, Guénaëlle, Christian Créveuil, Solenn Brosseau, et al.. (2025). MiR-193b-3p and miR-132-3p as prognostic biomarkers of survival in pleural mesothelioma patients treated with first-line bevacizumab plus pemetrexed-platinum chemotherapy in the IFCT-0701 MAPS phase 3 trial. Translational Oncology. 61. 102520–102520. 1 indexed citations

Guisier, Florian, Pernelle Lavaud, Laurent Greillier, et al.. (2024). Lurbinectedin in extensive-stage small-cell lung cancer: a brief report of the IFCT-2105 LURBICLIN study. ESMO Open. 9(12). 103968–103968. 2 indexed citations

Salas, Sébastien, Frédéric Ginot, Laurent Greillier, et al.. (2024). 137P Long circulating-free DNA fragments predict early-progression (EP) and progression-free survival (PFS) in advanced carcinoma treated with immune-checkpoint inhibition (ICI): A new biomarker. Annals of Oncology. 35. S270–S270. 1 indexed citations

Ciccolini, Joseph, et al.. (2024). Standard atezolizumab leads to severe overexposure in real-world patients with lung cancer: How far could we go in extending dosing intervals and saving money?. Journal of Clinical Oncology. 42(16_suppl). 3085–3085. 2 indexed citations

Tagliamento, Marco, Marie Morfouace, Júlio Oliveira, et al.. (2024). EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers. npj Precision Oncology. 8(1). 37–37. 6 indexed citations

Guisier, Florian, Charles Ricordel, Seyyid Baloglu, et al.. (2024). Outcomes of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with the Upfront Single Agent Pembrolizumab: A Retrospective and Multicentric Study of the ESCKEYP GFPC Cohort. Current Oncology. 31(3). 1656–1666. 2 indexed citations

Goss, Geraldine, Gail Darling, Virginie Westeel, et al.. (2024). LBA48 CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC). Annals of Oncology. 35. S1238–S1238. 17 indexed citations

10.

Ghiringhelli, François, Enriqueta Felip, Alona Zer, et al.. (2023). 1441P Atezolizumab and bevacizumab (atezo + bev) ± radiotherapy (RT) vs docetaxel (doc) in checkpoint inhibitor (CPI)–experienced metastatic NSCLC (mNSCLC): Results from the phase Ib/II MORPHEUS-lung study. Annals of Oncology. 34. S819–S820. 4 indexed citations

11.

Macagno, Nicolas, Laurent Greillier, M.‐A. Richard, et al.. (2023). Étude de cohorte évaluant la toxicité cutanée des anticorps bispécifiques anti-EGFR et anti-MET seuls ou en association aux inhibiteurs d’EGFR. 3(8). A145–A145.

12.

Gorvel, Laurent, Sonia Pastor, Clara Degos, et al.. (2023). Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors. Journal for ImmunoTherapy of Cancer. 11(5). e006348–e006348. 13 indexed citations

13.

Yang, James Chih‐Hsin, Paul Mitchell, Thomas John, et al.. (2023). 1325P Sunvozertinib as first-line treatment in NSCLC patients with EGFR Exon20 insertion mutations. Annals of Oncology. 34. S765–S765. 7 indexed citations

14.

Remón, Jordi, Nicolas Girard, Silvia Novello, et al.. (2021). PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients. Clinical Lung Cancer. 23(3). e243–e246. 24 indexed citations

15.

Auliac, J.B., I. Monnet, Laurent Greillier, et al.. (2021). Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02–15 study). Lung Cancer. 161. 122–127. 3 indexed citations

16.

Eberst, Guillaume, Amélie Anota, Arnaud Scherpereel, et al.. (2019). Health-Related Quality of Life Impact from Adding Bevacizumab to Cisplatin-Pemetrexed in Malignant Pleural Mesothelioma in the MAPS IFCT-GFPC-0701 Phase III Trial. Clinical Cancer Research. 25(19). 5759–5765. 15 indexed citations

17.

Morgensztern, Daniel, Benjamin Besse, Laurent Greillier, et al.. (2019). Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study. Clinical Cancer Research. 25(23). 6958–6966. 229 indexed citations

18.

Bermudez, Julien, Céline Mascaux, Youssef Trigui, et al.. (2019). Predictive Factors of Intracranial Response of Immune Checkpoint Inhibitors in Patients with Brain Metastasis from Non-Small Cell Lung Cancer. Journal of Cancer Therapy. 10(8). 692–707.

19.

Tomasini, Pascale, et al.. (2019). First-line pembrolizumab in programmed death ligand 1 positive non-small cell lung cancer. Translational Cancer Research. 8(7). 2514–2516. 5 indexed citations

20.

Grosso, Federica, Nicola Steele, Silvia Novello, et al.. (2017). Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. Journal of Clinical Oncology. 35(31). 3591–3600. 77 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact